Does Theravance Biopharma Inc – Ordinary Shares (NASDAQ:TBPH) Have Gas After Even More Sellers Involved?

September 30, 2018 - By Kristin Houston

Theravance Biopharma, Inc. (NASDAQ:TBPH) Logo

Investors sentiment decreased to 1.09 in 2018 Q2. Its down 0.26, from 1.35 in 2018Q1. It turned negative, as 10 investors sold Theravance Biopharma, Inc. shares while 25 reduced holdings. 12 funds opened positions while 26 raised stakes. 35.37 million shares or 0.68% less from 35.61 million shares in 2018Q1 were reported.
Voya Limited Co reported 17,575 shares. First Manhattan has 0.08% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH). 22,204 were accumulated by Invesco Limited. State Common Retirement Fund reported 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Daiwa Gru has 299 shares for 0% of their portfolio. State Of New Jersey Common Pension Fund D invested 0.02% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). The California-based California Pub Employees Retirement Systems has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Nj State Employees Deferred Compensation Plan has invested 0.14% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Goldman Sachs Group has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Parametric Portfolio Limited Liability owns 13,139 shares. Armistice Limited Com has invested 1.75% of its portfolio in Theravance Biopharma, Inc. (NASDAQ:TBPH). Senzar Asset Ltd Liability owns 27,397 shares. The Ontario – Canada-based Royal Financial Bank Of Canada has invested 0% in Theravance Biopharma, Inc. (NASDAQ:TBPH). Blackrock owns 0% invested in Theravance Biopharma, Inc. (NASDAQ:TBPH) for 3.75 million shares. Proshare Ltd holds 28,696 shares.

Since May 18, 2018, it had 1 buy, and 5 selling transactions for $2.11 million activity. 14,040 shares were sold by Shafer Bradford J, worth $336,527 on Wednesday, June 6. GALA RENEE D sold $242,877 worth of Theravance Biopharma, Inc. (NASDAQ:TBPH) on Friday, May 18. MALKIEL BURTON G bought $22,540 worth of stock or 1,000 shares.

The stock of Theravance Biopharma Inc – Ordinary Shares (NASDAQ:TBPH) registered an increase of 0.44% in short interest. TBPH’s total short interest was 6.02M shares in September as published by FINRA. Its up 0.44% from 6.00M shares, reported previously. With 138,600 shares average volume, it will take short sellers 44 days to cover their TBPH’s short positions. The short interest to Theravance Biopharma Inc – Ordinary Shares’s float is 18.07%.

The stock increased 4.81% or $1.5 during the last trading session, reaching $32.67. About 818,716 shares traded or 271.11% up from the average. Theravance Biopharma, Inc. (NASDAQ:TBPH) has declined 11.71% since September 30, 2017 and is downtrending. It has underperformed by 27.33% the S&P500.

Theravance Biopharma, Inc., a diversified biopharmaceutical company, discovers, develops, and commercializes human therapeutics. The company has market cap of $1.80 billion. The firm offers VIBATIV , a bactericidal, once-daily injectable antibiotic to treat patients with infections due to Staphylococcus aureus and other Gram-positive bacteria. It currently has negative earnings. The Company’s product candidates include TD-1792 that is in phase III clinical trials for the treatment of skin and soft tissues infections; TD-6450, a multivalent NS5A inhibitor, which is in Phase II study for Hepatitis C Virus; and Revefenacin (TD-4208), a long acting muscarinic antagonist that is in Phase III clinical studies for chronic obstructive pulmonary diseases.

More important recent Theravance Biopharma, Inc. (NASDAQ:TBPH) news were published by: Streetinsider.com which released: “Theravance Biopharma (TBPH) Highlights Positive CHMP Opinion Supporting Expanded COPD Indication for Trelegy …” on September 24, 2018, also Streetinsider.com published article titled: “Theravance Biopharma (TBPH), Mylan (MYL) Announce New Data from Phase 3 Studies of YUPELRI (revefenacin) at …”, Streetinsider.com published: “Theravance (TBPH), Mylan (MYL) to Report New Data from Phase 3 Studies of YUPELRI in Oral Presentation at ERS” on September 11, 2018. More interesting news about Theravance Biopharma, Inc. (NASDAQ:TBPH) was released by: Seekingalpha.com and their article: “Your Daily Scoop: Unum’s Positive Data, Theravance’s Treatment Benefit, Collectar’s New Designation” with publication date: September 21, 2018.

Theravance Biopharma, Inc. (NASDAQ:TBPH) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: